AbbVie to Acquire Apogee Therapeutics for $10.9 Billion — Apogee Therapeutics, Inc.

Event summary

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion.
Positive Phase 2 APEX Part B results support planned advancement of zumilokibart into Phase 3 development for moderate-to-severe atopic dermatitis this year.
Apogee secured up to $1.3 billion in strategic financing from Blackstone Life Sciences to support Phase 3 development and potential commercialization of zumilokibart.
Cash position as of June 30, 2026, was $1.3 billion, compared to $621.2 million as of June 30, 2025.

The big picture

AbbVie's acquisition of Apogee Therapeutics underscores the strategic importance of bolstering its immunology portfolio with differentiated assets. The deal comes at a time when biotech M&A activity is surging, driven by the need for large pharma companies to secure innovative pipelines. Apogee's positive Phase 2 data for zumilokibart positions it as a key asset in addressing moderate-to-severe atopic dermatitis and other inflammatory diseases.

What we're watching

Deal Closure Timing: The pace at which the acquisition by AbbVie closes, subject to shareholder approval and regulatory clearances.
Clinical Trial Success: Whether zumilokibart can maintain its positive Phase 2 results in larger, potentially registrational Phase 3 trials.
Integration Strategy: How AbbVie plans to integrate Apogee's pipeline into its existing immunology portfolio and commercialization strategy.